CXCL9 and neoplasm: Moreover, the CXCL9, 10, or 11–CXCR3 ligand/receptor pair has also been reported to be downregulated in the metastatic and therapy-resistant tumor, which suggested the upregulation of CXCL9, 10, and 11 might be potential therapy targets for recurrent tumors (Szekely et al., 2018).